Journal of Neuro-Oncology

, Volume 82, Issue 1, pp 91–93 | Cite as

A lipoxygenase inhibitor in breast cancer brain metastases

Clinical–Patient Studies

Abstract

The complication of multiple brain metastases in breast cancer patients is a life threatening condition with limited success following standard therapies. The arachidonate lipoxygenase pathway appears to play a role in brain tumor growth as well as inhibition of apoptosis in in-vitro studies. The down regulation of these arachidonate lipoxygenase growth stimulating products therefore appeared to be a worthwile consideration for testing in brain metastases not responding to standard therapy. Boswellia serrata, a lipoxygenase inhibitor was applied for this inhibition. Multiple brain metastases were successfully reversed using this method in a breast cancer patient who had not shown improvement after standard therapy. The results suggest a potential new area of therapy for breast cancer patients with brain metastases that may be useful as an adjuvant to our standard therapy.

Keywords

Cancer Lipoxygenase Boswellia serrata  Oxidoreductase inhibitor  LOX inhibitors  Lipoxygenase inhibitor  Brain Cancer Breast Cancer Metastases Breast Cancer Remission Arachidonate: Oxygen oxidoreductase  Herceptin 

References

  1. 1.
    Kirsch D, Ledezma C, Mathews C et al (2005) Survival after brain metastases from brest cancer in the Trastuzumab era. J Clin Oncol 23(9):2114–2116PubMedCrossRefGoogle Scholar
  2. 2.
    Langer C, Mehta M (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23(25):6207–6219PubMedCrossRefGoogle Scholar
  3. 3.
    Loeffler JS, Kooy HM, Wen PY et al (1990) The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol 8:576–582PubMedGoogle Scholar
  4. 4.
    Giller CA, Berger BD (2005) New frontiers in radiosurgery for the brain and body. BUMC Proc 18:311–319Google Scholar
  5. 5.
    Hazuka MB, Burleson WD, Stroud DN et al (1993) Multiple brian metastases are associated with poor survival in patients treated with surgery and radiotherapy. J Clin Oncol 11:369–373PubMedGoogle Scholar
  6. 6.
    Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617PubMedCrossRefGoogle Scholar
  7. 7.
    Tang DG, Chen YQ, Honn KV (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 93:5241–5246PubMedCrossRefGoogle Scholar
  8. 8.
    Chen JK, Capdevila J, Harris RC (2001) Cytochrome P450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21(18):6322–6331PubMedCrossRefGoogle Scholar
  9. 9.
    Kelavkar UP, Badr KF (1999) Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. Proc Natl Acad Sci USA 96:4378–4383PubMedCrossRefGoogle Scholar
  10. 10.
    Reo GN, Alexander RW, Runge MS (1995) Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 96:842–847CrossRefGoogle Scholar
  11. 11.
    Boado RJ, Pardridge WM, Vinters HV, Black KL (1992) Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA 89:9044–9048PubMedCrossRefGoogle Scholar
  12. 12.
    Ghosh J, Myers CE (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95:13182–13187PubMedCrossRefGoogle Scholar
  13. 13.
    Ding XZ, Hennig R, Adrian TE (2003) Lipoxygenase and cyclooxygenase metabolism: new insights in treatement in chemoprevention of pancreatic cancer. Mol Cancer 2:10PubMedCrossRefGoogle Scholar
  14. 14.
    Noguchi M, Rose DP, Erashi M et al (1995) The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology 52:265–271PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Foundation for Collaborative Medicine and ResearchGreenwichUSA

Personalised recommendations